##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 12 (2025)

Passive RSV immunisation using nirsevimab in neonatal care: a structured multidisciplinary approach and immunisation data from a Swiss tertiary centre

Cite this as:
Swiss Med Wkly. 2025;155:4689
Published
23.12.2025

Summary

BACKGROUND: Respiratory syncytial virus (RSV) infection is a major cause of severe lower respiratory tract infections in newborns and young infants, especially during the winter season from October to March. In Switzerland, RSV infection represents a leading cause of hospital admissions among newborns. Since October 2024, a long-acting monoclonal antibody, nirsevimab (Beyfortus®), has been available in Switzerland for standard care in newborns.

OBJECTIVES: This paper presents a multidisciplinary, standardised protocol for the administration of nirsevimab, as well as immunisation data from the first season of application in 2024/25 at a tertiary centre in Switzerland.

METHODS: A protocol for implementing the RSV immunisation strategy was developed at University Hospital Zurich by a multidisciplinary team of obstetricians, neonatologists, nurses, from in- and outpatient services. The focus was on prenatal counselling during outpatient consultations as well as inpatient procedures on maternity and neonatology wards. The goal was to provide expectant parents with consistent information by different healthcare professionals. Neonatal immunisation data from the first season in 2024/25 (25 October to 31 March ) were retrieved from patient charts (Yes/No) in a retrospective, quality control, observational cohort study. All newborns discharged from the maternity ward or the neonatology unit of our centre were included in the analysis.

RESULTS: The protocol included early and multidisciplinary parental education, offering consistent oral and written information, as well as opportunities to discuss their questions regarding the new immunisation, ensured informed consent and enabled timely administration of nirsevimab by healthcare professionals in the obstetrics and neonatology units. Over the 2024/25 season, 78% of the newborns were immunised before leaving hospital care: 78% (588/758) of newborns discharged home from the maternity ward were immunised and 82% (125/153) of those discharged home from the neonatology unit were immunised.  

CONCLUSION: The implementation of passive RSV immunisation was overall successful with an immunisation rate of around 80% for the first season in 2024/25.

References

  1. 1. Mochizuki H, Kusuda S, Okada K, Yoshihara S, Furuya H, Simões EA, et al.; Scientific Committee for Elucidation of Infantile Asthma. Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study. Am J Respir Crit Care Med. 2017 Jul;196(1):29–38. doi: https://doi.org/10.1164/rccm.201609-1812OC
  2. 2. Simões EA, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Cabañas F, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023 Mar;7(3):180–9. doi: https://doi.org/10.1016/S2352-4642(22)00321-2
  3. 3. Ernst C, Bejko D, Gaasch L, Hannelas E, Kahn I, Pierron C, et al. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg. Euro Surveill. 2024 Jan;29(4):2400033. doi: https://doi.org/10.2807/1560-7917.ES.2024.29.4.2400033
  4. 4. Lassoued Y, Levy C, Werner A, Assad Z, Bechet S, Frandji B, et al. Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: a test-negative case-control study. Lancet Reg Health Eur. 2024 Jul;44:101007. doi: https://doi.org/10.1016/j.lanepe.2024.101007
  5. 5. López-Lacort M, Muñoz-Quiles C, Mira-Iglesias A, López-Labrador FX, Mengual-Chuliá B, Fernández-García C, et al. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Euro Surveill. 2024 Feb;29(6):2400046. doi: https://doi.org/10.2807/1560-7917.ES.2024.29.6.2400046
  6. 6. Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al.; MELODY Study Group. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022 Mar;386(9):837–46. doi: https://doi.org/10.1056/NEJMoa2110275
  7. 7. Svizzera; P.S.P.S.P., et al., Consensus statement / recommendation on the prevention of respiratory syncytial virus (RSV) infections with the monoclonal antibody Nirsevimab (Beyfortus®) 2024: https://www.infovac.ch
  8. 8. Swiss DR. Klarstellung zur Vergütung von Nirsevimab (RSB-Immunisierung für Neugeborene). 2025 15.01.2025]; Available from: https://www.swissdrg.org/application/files/6917/3693/8899/Klarstellung_zur_Verguetung_von_Nirsevimab.pdf
  9. 9. Bundesamt für Gesundheit. S., Respiratorisches Synzytial-Virus. RSV; 2024.
  10. 10. Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, et al.; HARMONIE Study Group. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. N Engl J Med. 2023 Dec;389(26):2425–35. doi: https://doi.org/10.1056/NEJMoa2309189
  11. 11. Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al.; Nirsevimab Study Group. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 Jul;383(5):415–25. doi: https://doi.org/10.1056/NEJMoa1913556
  12. 12. Zürcher SJ, Signorell A, Léchot-Huser A, Aebi C, Huber CA. Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: are we on track? Vaccine. 2023 Nov;41(48):7226–33. doi: https://doi.org/10.1016/j.vaccine.2023.10.043
  13. 13. Sabatini S, Kaufmann M, Fadda M, Tancredi S, Noor N, Van Der Linden BW, et al. Factors Associated With COVID-19 Non-Vaccination in Switzerland: A Nationwide Study. Int J Public Health. 2023 May;68:1605852. doi: https://doi.org/10.3389/ijph.2023.1605852
  14. 14. Krasselt J, Robin D, Fadda M, Geutjes A, Bubenhofer N, Suzanne Suggs L, et al. Tick-Talk: parental online discourse about TBE vaccination. Vaccine. 2022 Dec;40(52):7538–46. doi: https://doi.org/10.1016/j.vaccine.2022.10.055
  15. 15. Lafnitzegger A, Gaviria-Agudelo C. Vaccine Hesitancy in Pediatrics. Adv Pediatr. 2022 Aug;69(1):163–76. doi: https://doi.org/10.1016/j.yapd.2022.03.011
  16. 16. Wagner A, Juvalta S, Speranza C, Suggs LS, Drava J; COVIDisc study group. Let’s talk about COVID-19 vaccination: relevance of conversations about COVID-19 vaccination and information sources on vaccination intention in Switzerland. Vaccine. 2023 Aug;41(36):5313–21. doi: https://doi.org/10.1016/j.vaccine.2023.07.004
  17. 17. Bundesamt für Gesundheit. S., Nirsevimab zur Immunisierung gegen das Respiratorische Synzytial-Virus (RSV), in BAG-Bulletin, S. Bundesamt für Gesundheit, Editor. 2024. p. 8-18.
  18. 18. Bhugra P, Grandhi GR, Mszar R, Satish P, Singh R, Blaha M, et al. Determinants of Influenza Vaccine Uptake in Patients With Cardiovascular Disease and Strategies for Improvement. J Am Heart Assoc. 2021 Aug;10(15):e019671. doi: https://doi.org/10.1161/JAHA.120.019671
  19. 19. Ng QX, Ng CX, Ong C, Lee DY, Liew TM. Examining Public Messaging on Influenza Vaccine over Social Media: Unsupervised Deep Learning of 235,261 Twitter Posts from 2017 to 2023. Vaccines (Basel). 2023 Sep;11(10):1518. doi: https://doi.org/10.3390/vaccines11101518
  20. 20. Chao DL, Dimitrov DT. Seasonality and the effectiveness of mass vaccination. Math Biosci Eng. 2016 Apr;13(2):249–59. doi: https://doi.org/10.3934/mbe.2015001
  21. 21. Jin Hsieh TY, Cheng-Chung Wei J, Collier AR. Investigation of Maternal Outcomes Following Respiratory Syncytial Virus Vaccination in the Third Trimester: Insights from a Real-World U.S. Electronic Health Records Database. Am J Obstet Gynecol. 2025.
  22. 22. Kafadar AH, Sabatini S, Jones KA, Dening T. Categorising interventions to enhance vaccine uptake or reduce vaccine hesitancy in the United Kingdom: A systematic review and meta-analysis. Vaccine. 2024 Nov;42(25):126092. doi: https://doi.org/10.1016/j.vaccine.2024.06.059